Quantcast
Last updated on April 24, 2014 at 0:13 EDT

Latest The Michael J. Fox Foundation Stories

2014-04-23 16:29:24

NEW YORK, April 23, 2014 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation for Parkinson's Research (MJFF) is launching a new funding program to promote collaborative analysis of subtypes of the protein alpha-synuclein. Aggregating in the cells of all people with Parkinson's disease (PD), alpha-synuclein is a major target for drug development. To advance those efforts, scientists must analyze different species of this protein -- resulting from splicing or post-translational...

2014-04-11 08:24:27

LA JOLLA, Calif., April 11, 2014 /PRNewswire-iReach/ -- On March 4, 2014, ICB International, Inc., ("ICBI"), announced the development of a tracer for imaging alpha-synuclein (a-Syn) in Parkinson's-like mice at the Keystone Symposium for Parkinson disease (PD) in Keystone,Colorado. Speaking at the symposium, Dr. Anna Cartier, Associate Director of ICBI, presented scientific data and showed images for the first successful live visualization of a-Syn in the brains of mice with and...

2014-03-31 12:28:21

NEW YORK, March 31, 2014 /PRNewswire-USNewswire/ -- Results out of a study funded by The Michael J. Fox Foundation for Parkinson's Research (MJFF) have enabled researchers to secure a $23 million grant from the National Institutes of Health (NIH), continuing a repurposed drug approved for hypertension to Phase III testing for slowing Parkinson's progression. The trial investigating the compound isradipine will be the most advanced, current study into a disease-modifying therapy for...

2014-02-25 08:33:01

NEW YORK, Feb. 25, 2014 /PRNewswire-USNewswire/ -- The Parkinson's Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF), is expanding to study individuals with genetic mutations associated with Parkinson's disease (PD). Researchers hope that greater understanding of the biology and clinical features of these participants -- people with or at risk to develop Parkinson's -- will lead to...

2014-02-20 12:27:18

NEW YORK, Feb. 20, 2014 /PRNewswire-USNewswire/ -- As medical researchers across disease states pursue better treatments, they all share one limiting factor. Estimates hold that 85 percent of all studies face delays and 30 percent never get off the ground due to a lack of clinical research volunteers. Slow patient enrollment diminishes the scientific power of studies, drives costs up and, most notably, delays improved therapies for patients. Partnership of patients and scientists in clinical...

2014-02-18 08:32:53

Third Phase of Collaboration Aims to Unravel Mysteries of Disease by Identifying Disease Markers and Potential New Drug Targets FRAMINGHAM, Mass. and SUNNYVALE, Calif., Feb. 18, 2014 /PRNewswire/ -- Berg and the Parkinson's Institute and Clinical Center today announced the next phase in their ongoing partnership, focused on identifying potential biomarkers that may lead to breakthroughs in the research, diagnosis, and treatment of Parkinson's disease. Using Berg's Interrogative...

2014-02-05 12:27:55

Mounting Evidence of Biological Similarities Inspires Funding Program to Advance Understanding of Two Most Common Brain Diseases CHICAGO, NEW YORK and TORONTO, Feb. 5, 2014 /PRNewswire-USNewswire/ -- As research unveils overlap in the biology -- in addition to long-noted shared clinical symptoms -- of Parkinson's and Alzheimer's diseases, three non-profit organizations are uniting to encourage further study into the similarities and differences between the two most common brain diseases,...

2014-01-29 12:27:59

NEW YORK, Jan. 29, 2014 /PRNewswire-USNewswire/ -- Research projects from three biopharmaceutical companies in the United States comprise the 2013 second half (2H 2013) of The Michael J. Fox Foundation for Parkinson's Research (MJFF) Partnering Program. Among the most promising in the MJFF portfolio, Partnering Program participants' research projects are presented directly to industry groups who may wish to invest in further development of the project. By connecting industry leaders...

2013-12-26 12:21:02

Potential Neuroprotective Therapy Ready for Next Stage of Development after Michael J. Fox Foundation Funding NEW YORK, Dec. 26, 2013 /PRNewswire-USNewswire/ -- New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease (PD) show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout. Previous research showed that higher levels of the antioxidant urate were...

2013-12-19 08:28:23

- Novel Approach to Target Disease-driving Misfolded Proteins - CAMBRIDGE, Mass., Dec. 19, 2013 /PRNewswire/ -- NeuroPhage Pharmaceuticals, Inc. today announced that it has been awarded an $822,000 grant by The Michael J. Fox Foundation for Parkinson's Research (MJFF) for its second-generation drug candidate, NPT088, based on NeuroPhage's GAIM (general amyloid interaction motif) platform, which simultaneously targets multiple misfolded proteins central to many neurodegenerative...